Table 2.
Survey Respondent Product Characteristics
| Characteristics | Respondents, n (%) |
|---|---|
| Product Development Stage (Total) | 126 |
| Early clinical (phases I–II) | 91 (72) |
| Late clinical (phase III) | 16 (13) |
| Regulatory approval | 7 (6) |
| Commercialization | 12 (10) |
| Intended Therapeutic Area | |
| Oncology | 36 (29) |
| Ophthalmology | 19 (15) |
| Hematology | 18 (14) |
| Orthopedics and skeletal | 12 (10) |
| Immunology | 9 (7) |
| Gastroenterology | 8 (6) |
| Cardiovascular | 8 (6) |
| Neurology | 5 (4) |
| Dermatology | 4 (3) |
| Other | 7 (6) |
| Pediatric Indication | |
| Yes (<18 years) | 51 (40) |
| No (≥18 years) | 75 (60) |
| Orphan Indication | |
| Yes | 69 (55) |
| No | 57 (45) |